Urocortin-2 (UCN2) is a selective corticotropin-releasing factor CRF2 receptor (CRFR2) agonist, which has been previously shown to reduce fat mass while promoting muscle hypertrophy. Hanmi Pharmaceutical Co. Ltd. presented the discovery and preclinical characterization of a novel CRFR2-selective UCN2 analogue, HM-17321, being developed for the treatment of obesity.
Novo Nordisk A/S has identified novel fatty acid modified urocortin 2 derivatives acting as CRF2 receptor agonists reported to be useful for the treatment of obesity and type 2 diabetes.
